Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Pechala's Reports
$25.00
Provider: New Constructs, LLC
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Cell Therapeutics Inc Announces Market Access Granted in France for Aggressive Non-Hodgkin Lymphoma Treatment PIXUVRI


Monday, 19 Aug 2013 01:31am EDT 

Cell Therapeutics Inc (CTI) announced that the Transparency Commission (Commission de la Transparence or CT) of the French National Health Authority (Haute Autorite de Sante or HAS) has granted market access for the medicinal product PIXUVRI (pixantrone) as a monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (patients with aggressive B-cell NHL who failed two or three prior lines of therapy). The next and final step in France‚Äôs pharmaceutical reimbursement process is inclusion on the list of medicines approved for hospital use and subsequent publication in the Journal Officiel in France, which CTI intends to pursue. 

Company Quote

3.07
0.08 +2.68%
17 Apr 2014